focus -WSS

focus

author：explore 2025-09-09 05:35:39 - browse：797

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Patient advocates debate FDA's accelerated approval process

focus

WSS

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Senate panel eyes new effort on drug shortages

Analysis of telehealth claims data suggest service duplication

Oprah kicked off a national conversation on obesity. Let's have it

The Readout: Lenmeldy, GLP

The Readout: Lenmeldy, GLP

explore

focus

Wikipedia

Psychedelics group wrestles with new pharma identity

Roche subsidiary Foundation Medicine opens new headquarters

Apple is now the first public company to be valued at $3 trillion

Why the world’s most expensive drug might be worth the price

State Dept. review finds Biden bears some blame for Afghanistan failures

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Dobbs anniversary: the lost opportunity of abortion as health care

Colorectal cancer study finds potential in overlooked immune cell

ChatGPT in medicine: STAT answers readers' burning questions

States should stop sabotaging methadone treatment reform

leisure time

Why Charlie Gard's case is so disturbing to Americans

Oprah kicked off a national conversation on obesity. Let's have it

Abortion pill Supreme Court ruling could impact entire drug industry

States should stop sabotaging methadone treatment reform

Stroke deaths set to near 10 million globally by 2050

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

focus

focus

focus

entertainment